• 1
    Sekeres M,Fu A,Maciejewski J,Golshayan A,Kalaycio M,Kattan M. A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes. Blood. 2005; 106: 711a.
  • 2
    Silverman L. The Myelodysplastic Syndrome. In: HollandJ, FreiE, BastR, KufeD, MortonD, WeichselbaumR, eds. Cancer Medicine. Baltimore: Williams and Wilkins; 1996: 25932615.
  • 3
    List AF,Vardiman J,Issa JP,DeWitte TM. Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program). 2004: 297317.
  • 4
    Greenberg P,Cox C,LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89: 20792088.
  • 5
    Malcovati L,Germing U,Kuendgen A, et al. A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes. Blood. 2005; 106: 232a.
  • 6
    Bennett JM,Catovsky D,Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982; 51: 189199.
  • 7
    Harris NL,Jaffe ES,Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol. 1999; 10: 14191432.
  • 8
    Allampallam K,Shetty V,Mundle S, et al. Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol. 2002; 75: 289297.
  • 9
    Bellamy WT,Richter L,Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood. 2001; 97: 14271434.
  • 10
    Kitagawa M,Saito I,Kuwata T, et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia. Dec 1997; 11: 20492054.
  • 11
    Cheson BD,Bennett JM,Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000; 96: 36713674.
  • 12
    Cheson BD,Bennett JM,Kantarjian H, et al. Myelodysplastic syndromes standardized response criteria: further definition. Blood. 2001; 98: 1985.
  • 13
    Hellstrom-Lindberg E,Negrin R,Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol. Nov 1997; 99: 344351.
  • 14
    Hellstrom-Lindberg E,Gulbrandsen N,Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol. Mar 2003; 120: 10371046.
  • 15
    Jadersten M,Montgomery SM,Dybedal I,Porwit-MacDonald A,Hellstrom-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood. 2005; 106: 803811.
  • 16
    Lee SJ,Kuntz KM,Horowitz MM, et al. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med. 1997; 127: 10801088.
  • 17
    Ng AK,Weeks JC,Mauch PM,Kuntz KM. Decision analysis on alternative treatment strategies for favorable-prognosis, early-stage Hodgkin's disease. J Clin Oncol. 1999; 17: 35773585.
  • 18
    Ng AK,Weeks JC,Mauch PM,Kuntz KM. Laparotomy versus no laparotomy in the management of early-stage, favorable-prognosis Hodgkin's disease: a decision analysis. J Clin Oncol. 1999; 17: 241252.
  • 19
    Cutler CS,Lee SJ,Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004; 104: 579585.
  • 20
    Sonnenberg FA,Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993; 13: 322338.
  • 21
    Silverman LR,Demakos EP,Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002; 20: 24292440.
  • 22
    Yamada T,Tsurumi H,Kasahara S,Hara T,Sawada M,Moriwaki H. Immunosuppressive therapy for myelodysplastic syndrome: efficacy of methylprednisolone pulse therapy with or without cyclosporin A. J Cancer Res Clin Oncol. 2003; 129: 485491.
  • 23
    Kantarjian H,Issa JP,Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106: 17941803.
  • 24
    Spiriti MA,Latagliata R,Niscola P, et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol. 2005; 84: 167176.
  • 25
    Sekeres MA,Stone RM,Zahrieh D, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004; 18: 809816.
  • 26
    Kornblith AB,Herndon JE2nd,Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002; 20: 24412452.
  • 27
    Gulbrandsen N,Wisloff F,Nord E,Lenhoff S,Hjorth M,Westin J. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur J Haematol. 2001; 66: 328336.
  • 28
    Bloomfield DJ,Krahn MD,Neogi T, et al. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol. 1998; 16: 22722279.
  • 29
    National Center for Health Statistics. Vital Statistics of the United States, 1999, Mortality. Hyattsville, MD: Public Health Service; 2004.
  • 30
    List A,Kurtin S,Roe D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005; 352.
  • 31
    List A,Dewald G,Bennett J, et al. Hematologic and cytogenetic (CTG) response to lenalidomide (CC-5013) in patients with transfusion-dependent (TD) myelodysplastic syndrome (MDS) and chromosome 5q31.1 deletion: results of the multicenter MDS-003 study. J Clin Oncol (Proc Am Soc Clin Oncol). 2005; 23: 2s.